Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 28 entities : Eli lilly and company save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
F-Secure Becomes Cybersecurity Awareness Month 2021 Champion
Published: 2021-09-28 (Crawled : 15:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
MAR | News | $244.04 1.82% 1.78% 2.3M
|
Consumer Services
|
| O: -0.77%
H: 1.42%
C: 0.3%
security cybersecurity
Care Access and Eli Lilly and Company Partner to Increase Diversity Within Oncology Clinical Trials
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
clinical trials trials trial
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: -1.28%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -7.01%
H: 2.22%
C: -1.77%
alcohol use disorder treatment phase 1 trial
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Published: 2021-09-28 (Crawled : 07:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
collaboration license
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
Published: 2021-09-28 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.27%
H: 0.81%
C: -0.56%
collaboration license
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.